Aurobindo Pharma rises 3% after firm's clarification on FDA observations

Shares of Aurobindo Pharma recovered over 3 per cent on Wednesday after the company clarified that none of the seven observations from the US health regulator for its Telangana unit were linked to data integrity.

In a regulatory filing post market hours on Monday, Aurobindo Pharma said that it is "confident of addressing these issues within the stipulated timeline".

The equity market was closed on Tuesday on account of Dussehra.

Shares of the company opened on a strong note at Rs 472, then gained further ground and touched a high of Rs 485, registering a jump of 5.46 per cent. The scrip finally settled at Rs 474.30, up 3.45 per cent over previous close on the BSE.

On the NSE, the stock gained 3.16 per cent to close at Rs 474.40.

The exchange had sought a clarification from the company regarding declining share prices on the back of USFDA observations.

Shares of Aurobindo Pharma had slumped over 19 per cent and had hit its 52-week low of Rs 450 on Monday after the US health regulator issued seven observations.

The United States Food and Drug Administration (USFDA) conducted a Current Good Manufacturing Practices (CGMP) inspection at the company's unit-7 manufacturing facility from September 19 to 27, Aurobindo Pharma had said in a BSE filing.

The inspection ended with seven observations, it added.

"We believe none of the observations are related to data integrity. The company is confident of addressing these issues within the stipulated timeline," it said.



Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel